Cytochroma Announces Positive Comparative Data on CTA018 in Chronic Kidney Disease Model
CTA018 Confers Therapeutic and Safety Advantages Over Current Therapies MARKHAM, Ontario, Nov. 6 /PRNewswire/ -- Cytochroma today announced positive comparative data on a novel vitamin D analog, CTA018, at the 2008 Annual Meeting of the American Society of Nephrology (ASN) in Philadelphia. I...Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
...itial top-line results from this trial showed that cta018 was safe and well tolerated. Complete study result...pen label, placebo-controlled, randomized study of cta018 Injection administered to 20 healthy volunteers. I... (PTH) was observed in this trial, suggesting that cta018 has potential as a treatment for secondary hyperpa...Cytochroma Appoints R. Richard Wieland II As CFO
...reaching more than $1.2 billion annually by 2010 in North America alone. Cytochroma has three lead product candidates in development for CKD patients: cta018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitam...Cytochroma opens U.S. headquarters in Illinois
...reaching more than $1.2 billion annually by 2010 in North America alone. Cytochroma has three lead product candidates in development for CKD patients: cta018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitam...